Suprefact · GnRH agonist (buserelin)
GnRH agonist — prostate cancer and sex hormone modulation.
FDA
Approved
WADA
Banned
HALF-LIFE
~1.2 hours
ROUTE
Intranasal, SubQ injection, or implant
SCHEDULE
3× daily intranasal or monthly implant
In Plain English
GnRH agonist — prostate cancer and sex hormone modulation.
Status & Legality
NATTY?
Not NattyWADA banned substance. Tested athletes will fail.
FDA
ApprovedFDA approved for human use.
WADA
BannedOn WADA prohibited list. Use disqualifies in tested sports.
COMPOUNDING
Rx AvailableAvailable at licensed pharmacies with prescription.
PRESCRIBED
By prescriptionPhysicians can prescribe this compound legally.
ROUTE
Intranasal, SubQ injection, or implantAdministration via intranasal, subq injection, or implant.
Prostate cancer
Endometriosis
Testosterone suppression
IVF protocols
Buserelin is a potent GnRH agonist approved for prostate cancer and endometriosis. Like leuprolide and triptorelin, chronic use causes pituitary desensitization and profound sex hormone suppression. Unique among GnRH agonists for its intranasal formulation, making it practical for clinical use without injections.
Hot flashes
Bone density loss (long-term)
Sexual dysfunction
Depression
Initial testosterone flare
Confusing intranasal Buserelin's low bioavailability (~3%) with injectable forms — intranasal requires much higher doses than subcutaneous injection to achieve equivalent effects
Not managing the initial testosterone flare in prostate cancer — the first week causes a temporary testosterone rise before suppression begins; concurrent antiandrogen is often needed
Using as a research compound without understanding it causes testosterone suppression — the hormonal effect is profound and not reversible quickly after depot doses
Antiandrogens (bicalutamide, flutamide) — used clinically during initial testosterone flare management in prostate cancer
Bone-density medications — often co-prescribed for long-term use; androgen deprivation causes significant bone loss
Antidiabetics — androgen deprivation worsens insulin resistance; adjust diabetes management accordingly
Buserelin is a medical compound for hormone-sensitive conditions — primarily prostate cancer, endometriosis, and IVF protocols. Its intranasal availability is clinically convenient for daily dosing, but the 3% bioavailability means doses are very different from injectable forms. Any use outside supervised medical care requires extreme caution.
Stats
Sources & Studies
Buserelin (HOE 766), a potent GnRH analog: clinical applications in prostate cancer
Peeling WB. et al., J Urol, 1985